Figure 3.

 Telbivudine therapy improves survival rate, clinical conditions and histological lesions in MHV‐3‐infected C3H mice. Fifteen animals in each group received either telbivudine or PBS for 15 days. (a) Survival rates in the telbivudine group increased to 63.6% when compared with the PBS group (18.2%). (b) Composite clinical scores: scores were calculated for fur texture, respiration and tremor. Data are the mean examination of three animals per group scored in a blinded fashion. (c) Histological improvement: at 15 days after infection, hepatic necrosis was minimized post telbivudine treatment (arrows).